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Background. To characterize the lung tumor volume response during conventional and hypofractionated radiotherapy (RT) based
on diagnostic quality CT images prior to each treatment fraction. Methods. Out of 26 consecutive patients who had received CTon-rails IGRT to the lung from 2004 to 2008, 18 were selected because they had lung lesions that could be easily distinguished. The
time course of the tumor volume for each patient was individually analyzed using a computer program. Results. The model fits of
group L (conventional fractionation) patients were very close to experimental data, with a median Δ% (average percent difference
between data and fit) of 5.1% (range 3.5–10.2%). The fits obtained in group S (hypofractionation) patients were generally good, with
a median Δ% of 7.2% (range 3.7–23.9%) for the best fitting model. Four types of tumor responses were observed—Type A: “high”
kill and “slow” dying rate; Type B: “high” kill and “fast” dying rate; Type C: “low” kill and “slow” dying rate; and Type D: “low”
kill and “fast” dying rate. Conclusions. The models used in this study performed well in fitting the available dataset. The models
provided useful insights into the possible underlying mechanisms responsible for the RT tumor volume response.

1. Introduction
Understanding lung tumor volume changes during radiotherapy may one day help radiation oncologists optimize
dose fractions and radiosensitizing strategies for individual
patients. A small number of studies have described lung
tumor volume changes during conventionally fractionated
external beam radiotherapy [1–5]. Lung tumor changes during hypofractionated radiotherapy, especially when delivered

in short courses (≤2 weeks), are less well understood. Four
studies have included patients receiving hypofractionated
treatments to varying degrees [6–9], and one study included
only large fraction (>7.5 Gy) hypofractionated RT [8].
Normal cell proliferation is based on the cell cycle,
through which cells duplicate their genome and protein
mass, enter mitosis, and divide. Cancer is essentially a
proliferative disorder resulting from uncontrolled cell cycling
of transformed cells which encode modified regulatory

2
proteins. For a given normal tissue or cancer, a fraction of
the cells is physiologically out of the cycle (quiescent, or
“𝐺0” cells), although they may enter the cycle with suitable
signals. The expansion of a cell population depends on the
balance between three phenomena: cell cycling, the quiescence/cycling balance, and cell death. This balance is strictly
controlled in normal tissues but is dysregulated in cancer
due to reduced cell death or quiescence and/or increased
cell cycling which causes accelerated expansion of the cell
population. Notably, proliferation features are variable within
a cell population given that the cell cycle length (𝑇𝑐) is highly
heterogeneous. Mathematical modeling of this phenomenon
has a long history [10], and it is theoretically grounded by
several works [11–14]. The tumor growth model adopted
here is not needlessly complicated while accounting for the
basic processes of cell cycling, quiescence, and cell loss [15].
The model was modified to account for treatment efficacy,
based on a simple description of cell killing and resistance,
and was proven suitable for fitting time courses of tumor
volumes when measured by calipers during neoadjuvant
breast cancer chemotherapy [16]. In this study, we use this
mathematical model to interpret time courses of nonsmall
cell lung cancer (NSCLC) tumor volumes measured by CT
scans during conventionally fractionated or hypofractionated
radiotherapy (RT).

2. Materials and Methods
A retrospective review of our IGRT database at East Carolina University identified 26 consecutive patients who had
received CT-on-rails IGRT (CTVision, Siemens, Malvern,
PA) to the lung from September of 2004 to November of
2008. The CT-on-rails system consists of a CT scanner and
a linear accelerator opposing each other in the treatment
vault and sharing the patient couch. The daily CT was of
diagnostic quality and was always obtained prior to treatment.
Of the 26 patients identified, 18 were selected because
they had lung lesions that could be easily distinguished from
other mediastinal structures and also underwent daily IGRT
during treatment. The lesions were predominantly spherical
in nature and surrounded by lung parenchyma which eased
the contouring process. Twelve patients were treated with
fractions ≤600 cGy, and 5 (Table 1, patients L1–L5, group L =
long) met the criteria for this analysis. Fourteen patients were
treated with fractions ≥1000 cGy, and 13 (Table 1, patients S1–
S13, group S = short) met the criteria for this analysis. Group
S, the hypofractionation group, completed treatment in less
than 14 days.
Patient S9, with an initial tumor volume of 0.4 cc, had
close to a fivefold increase in volume in the three days that
elapsed from the penultimate fraction to the last fraction due
to atelectasis and was excluded from the analysis.
The planning CT was obtained with a 3 mm slice thickness and with the patient in the supine position. To minimize
human bias, the tumor lesions were contoured in the planning CT using the CMS Xio (Release 4.34.02, St. Louis, MO)
treatment planning software’s (TPS) autothreshold contouring tool (𝑊 = 500, 𝐿 = 0). The TPS reports the tumor volume
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based on all the contours comprising a given tumor. The same
procedure was done to estimate the tumor volume on the
daily treatment CT, and additional diagnostic CT scans, preor posttreatment, when available.
2.1. Model Description. The time course of the tumor volume
for each patient was individually analyzed using a previously
described [16] computer program that allows for testing
different models of tumor growth and therapy efficacy (Figure
1). The tumor growth model is based on the equilibrium
between cycling cells, quiescent cells, and cell loss, resulting in
exponential growth. Although growth retardation is expected
when the tumor volume increases, the exponential growth
model is a very reasonable approximation during an observation range of a few weeks to months. The tumor growth
model is based on the age-structured cell cycle mathematical
theory of Bertuzzi et al. [15]. Tumor growth is defined by four
parameters: doubling time (𝑇𝑑), growth fraction (𝐺𝐹, i.e., the
fraction of cycling cells), cell cycle duration (𝑇𝑐), and the rate
“𝛾” at which quiescent cells reenter the cycle. Other model
parameters like the cell loss rate (𝜇𝑞 ), potential doubling time
(𝑇pot ), and the fraction of newborn cells bypassing 𝐺0 (𝜃)
are calculated from the previous four parameters [16]. The
equations for the number of cycling (𝑁𝑝) and quiescent (𝑁𝑞)
cells in our discrete model of exponential growth were the
following:
𝑁𝑝 (𝑡) = 𝑁𝑝 (𝑡 − Δ𝑡) + 𝜃 × 2𝑢 × 𝑁𝑝 (𝑡 − Δ𝑡) Δ𝑡
− 𝑢 × 𝑁𝑝 (𝑡 − Δ𝑡) Δ𝑡 + 𝛾 × 𝑁𝑞 (𝑡 − Δ𝑡) Δ𝑡 ,
𝑁𝑞 (𝑡) = 𝑁𝑞 (𝑡 − Δ𝑡) + (1 − 𝜃) × 2𝑢 × 𝑁𝑝 (𝑡 − Δ𝑡) Δ𝑡

(1)

− (𝛾 + 𝜇𝑞 ) × 𝑁𝑞 (𝑡 − Δ𝑡) Δ𝑡 ,
where 𝑢 is the rate at which cycling cells end the cell cycle,
linked to 𝑇𝑐 and 𝑇𝑑 via the following relationship: 𝑢 =
ln(2)/(𝑇𝑑 × (𝑒ln(2)×(𝑇𝑐/𝑇𝑑) − 1)), and Δ𝑡 = (𝑒ln(2)×(Δ𝑡/𝑇𝑑) −
1)/(ln(2)/𝑇𝑑) which connects the discrete model, acting with
step-time Δ𝑡, to the continuous model (Δ𝑡 → Δ𝑡, when
Δ𝑡 ≪ 𝑇𝑑). In this study we set Δ𝑡 = 1 day.
The dependent parameters are provided by the following
formulae, derived from the described theory [15]:
𝑇pot =
𝜇𝑞 =

(𝑒ln(2)×(𝑇𝑐/𝑇𝑑) − 1)
𝐺𝐹

× 𝑇𝑑,

ln (2) × (1/𝑇pot − (1/𝑇𝑑))
(1 − 𝐺𝐹)

,

(2)

(𝑒ln(2)×(𝑇𝑐/𝑇𝑑) /2) − 1
𝑒ln(2)×(𝑇𝑐/𝑇𝑑)
𝜗=
.
+𝛾×
2
(ln (2) /𝑇𝑑) + 𝜇𝑞
Once 𝑁(0) is given with 𝑇𝑑, 𝑇𝑐, 𝐺𝐹, and 𝛾, the time-zero
state variables are simply 𝑁𝑝(0) = 𝐺𝐹 × 𝑁(0) and 𝑁𝑞(0) =
(1 − 𝐺𝐹) × 𝑁(0). The ratio 𝑁𝑝/(𝑁𝑝 + 𝑁𝑞) remains equal to
𝐺𝐹 over time. The above equations describe the dynamics
of the unique asynchronous exponential growth associated
with a set of independent parameters. The choice of using
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Table 1: Individual patient, tumor, treatment, and tumor response characteristics. Patient IDs starting with an “L” had a long RT course while
those starting with an “S” had a short one.
Patient
ID

Sex

Age

Pathology

Total dose
(Gy)

Fx.
(Gy)

BED10 (Gy)

Days to
finish RT

Chemo

L1
L2
L3

M
M
F

68
78
75

SCCA
ACA
SCCA

75
75
75

93.8
93.8
93.8

46
43
44

No
Yes∗
No

L4

F

72

ACA

80

98.5

70

No

L5

M

69

ACA

66.6

2.5
2.5
2.5
2.5 (50 Gy)
2 (30 Gy)
1.8

78.6

55

No

S1
S2
S3
S4
S5
S6
S7
S8
S10
S11
S12
S13

F
F
F
F
M
M
F
M
F
F
M
M

65
66
68
61
70
85
69
73
74
82
74
66

SCCA
ACA
other†
NSCLC
ACA
ACA
SCCA
ACA
NSCLC
Other#
SCCA
SCCA

10
10
10
10
10
10
10
10
10
10
10
10

100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0

12
9
9
11
12
12
12
9
9
11
9
9

No
No
No‡
No
Yes§
No
No
No
No
No
No
No

50
50
50
50
50
50
50
50
50
50
50
50

Abbreviations:
ID: identifier; M: male; F: female; Fx.: daily fraction dose; BED10 : biologically effective dose, 𝛼/𝛽 ratio of 10; SCCA: squamous cell carcinoma; ACA:
adenocarcinoma; NSCLC: nonsmall cell lung cancer, not otherwise specified; RT: radiotherapy; chemo: chemotherapy.
∗
Three cycles of neoadjuvant paclitaxel (200 mg/m2 ) and carboplatin (AUC 5).
†
Clinical history consistent with metastatic breast adenocarcinoma.
‡
Patient completed chemotherapy for breast cancer 5 months prior to radiotherapy.
§
Biopsy proven recurrence after receiving 50 Gy in 2.5 Gy fractions. Received neoadjuvant, concurrent, and adjuvant erlotinib (150 mg) and bevacizumab
(15 mg/kg) for this course of RT.
#
Atypical cells suspicious for malignancy; serial CTs, PET/CT SUV ≥ 2.5, and clinical history consistent with primary lung malignancy.

parameters which are observable is convenient because it
allows to use their direct measure, when available, or to verify
the biological validity of the models. Data from the literature
suggests that typical values for 𝑇𝑑, 𝐺𝐹, and 𝑇pot are 100 days
[17–20], 0.2 [21, 22], and 8 days [18, 23], respectively, with a
wide interpatient variability of kinetic parameters in NSCLC.
In the present study, these four parameters were individually
estimated within the range described in the literature.
The equations are based on numbers of tumor cells, while
the data was tumor volume. We assumed that the measured
tumor volume was directly proportional to the number of
tumor cells, including those dying, assuming 109 cells = 1 cm3 .
However, the specific value of the proportionality constant
does not affect the results. The following four models of
radiation efficacy were considered.
Minimal (M) Model. The M, or simplest, model has no
differential efficacy between cycling and quiescent cells. The
parameters of the model are 𝐾 and 𝐷. The parameters
of quiescent cells (𝜃, 𝛾, and 𝐺𝐹) become irrelevant. The
effect is described by the percentage of cells killed (𝐾) by
a single fraction of radiotherapy. At the times of treatment
(𝑡tr ), the situation immediately before (𝑡tr −) the treatment is

considered separately from that immediately after (𝑡tr +) the
treatment, and the number of surviving, cycling, and quiescent cells is reduced according to the following:

𝑁𝑝 (𝑡tr +) = (1 −
𝑁𝑞 (𝑡tr ) = (1 −

𝐾
) × 𝑁𝑝 (𝑡tr −) ,
100
𝐾
) × 𝑁𝑞 (𝑡tr −) .
100

(3)

“Killed” cells are not immediately removed from the
tumor, but they are lost when they complete a three-stage
dying process with a single stage rate “𝐷.” In this way, the
time to definitive loss is a random variable whose probability
density function is the convolution of exponentials, also
known as the Erlang function. For example, 𝐷 = 0.75 means
75% of cells in dying stage I move to dying stage II in one
day, 75% in stage II move to stage III, and 75% in stage III are
definitely lost. With 𝐷 = 0.75 one can calculate that the dying
process takes an average four days before the disappearance
of the cells, six days when 𝐷 = 0.5, fifteen days when 𝐷 = 0.2,
and immediate (i.e., <3 days) loss when 𝐷 = 1.
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Standard model

Loss killed P cells

Loss killed Q cells

D

D

Dying P cells

Dying Q cells

D

D

Dying P cells

Dying Q cells

D

D

Dying P cells

Dying Q cells

Kp

Kq
Q (G0) cells

𝛾/𝛾rec

Proliferating cells
(with age distribution)

𝜇q

𝜃

Natural
cell loss

1−𝜃

Tc (cell cycle length)

×2

Figure 1: Block diagram of the proliferation model. A fraction 𝜃 of newborn cells directly enters the cycling stage, while the others (1 − 𝜃)
become quiescent (Q or 𝐺0). Quiescent cells either die (with a rate 𝜇0 ) or reenter into the cycling stage (with a “recycling” rate 𝛾). The
parameter 𝛾 is zero or very low (say no more than 0.01, meaning 1% of quiescent cells become cycling per day—otherwise these cells were
not “quiescent”). Cycling cells traverse the cell cycle (G1 + S + G2 M) in an average time 𝑇𝑐, after which they divide generating two newborn
cells. The parameters 𝜃 and 𝜇𝑞 are dependent on the input values of 𝑇𝑑, 𝐺𝐹, 𝑇𝑐, and 𝛾. Modeling of the proliferation is based on the general
mathematical theory of proliferating cell populations (see Ubezio and Cameron [16] and the references therein).

The following equations hold for the number of cells in
these stages (𝑁𝑑1 , 𝑁𝑑2 , and 𝑁𝑑3 , resp.):
𝑁𝑑1 (𝑡) = (1 − 𝐷) × 𝑁𝑑1 (𝑡 − Δ𝑡) ,
𝑁𝑑2 (𝑡) = (1 − 𝐷) × 𝑁𝑑2 (𝑡 − Δ𝑡) + 𝐷 × 𝑁𝑑1 (𝑡 − Δ𝑡) ,

(4)

𝑁𝑑3 (𝑡) = (1 − 𝑘𝐷) × 𝑁𝑑3 (𝑡 − Δ𝑡) + 𝐷 × 𝑁𝑑2 (𝑡 − Δ𝑡) ,
while at treatment times killed cells add to cells in the first
stage:
𝑁𝑑1 (𝑡tr +) = 𝑁𝑑1 (𝑡tr −) +

𝐾
× (𝑁𝑝 (𝑡tr −) + 𝑁𝑞 (𝑡tr −)) .
100
(5)

Standard (St) Model. The St model includes the differential
efficacy between cycling and quiescent cells. The parameters
of the model are 𝐾𝑝, 𝐾𝑞, and 𝐷. The effect is described
by the percentage of cycling (𝐾𝑝) and quiescent (𝐾𝑞) cells
killed by a single fraction. Thus, at treatment times the
number of cycling and quiescent cells is given by the following:
𝑁𝑝 (𝑡tr +) = (1 −

𝐾𝑝
) × 𝑁𝑝 (𝑡tr −) ,
100

𝐾𝑞
𝑁𝑞 (𝑡tr ) = (1 −
) × 𝑁𝑞 (𝑡tr −) .
100

(6)

Recruitment (REC) Model. The REC model allows a burst
of quiescent cells to enter the cell cycle at a specified
interval during treatment with a “recruitment rate” which

overperforms the pretreatment rate 𝛾. This model reflects the
concept of accelerated repopulation of the cycling tumor cell
pool. In normal conditions, the rate 𝛾 at which quiescent
cells go into the cycling stage is zero or very low. However,
it is possible that a fraction of quiescent cells is stimulated to
proliferate as a consequence of an RT treatment. This phenomenon is modeled here assuming that for a short period after
treatment, the value of 𝛾 becomes higher than 0.01, and the
parameter is renamed “𝛾rec .” The parameters of the model are
𝐾𝑝, 𝐾𝑞, 𝐷, and 𝛾rec .
Resistance (RES) Model. The RES model includes the presence
of radioresistant cells. The computer program allows for
testing two different resistance models: “initial resistance,”
assuming a subpopulation of resistant cells is already present
at the start of treatment (Rini being the fraction of resistant
cells at that time), and “induced resistance” assuming a
fraction of cells (Rind) becomes resistant after each RT
treatment. The same growth equations hold for sensitive and
resistant cells. The number of cycling and quiescent resistant
cells is indicated as 𝑁𝑟𝑝(𝑡) and 𝑁𝑟𝑞(𝑡), respectively.
In the case of resistant cells at the time of treatment, the
starting values are given by the following:
𝑁𝑝 (0) = 𝑁 (0) × 𝐺𝐹 × (1 − Rini) ,
𝑁𝑞 (0) = 𝑁 (0) × (1 − 𝐺𝐹) × (1 − Rini) ,
𝑁𝑟𝑝 (0) = 𝑁 (0) × 𝐺𝐹 × Rini,
𝑁𝑟𝑞 (0) = 𝑁 (0) × (1 − 𝐺𝐹) × Rini.

(7)
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In the case of induced resistance, the equations at the times
of treatment are modified as follows:
𝐾𝑝
) × 𝑁𝑝 (𝑡tr −) × (1 − Rind) ,
𝑁𝑝 (𝑡tr +) = (1 −
100
𝑁𝑞 (𝑡tr +) = (1 −

𝐾𝑞
) × 𝑁𝑞 (𝑡tr −) × (1 − Rind) ,
100

𝑁𝑟𝑝 (𝑡tr +) = 𝑁𝑟𝑝 (𝑡tr −) + (1 −

𝐾𝑝
) × 𝑁𝑝 (𝑡tr −) × Rind,
100

𝑁𝑟𝑞 (𝑡tr +) = 𝑁𝑟𝑞 (𝑡tr −) + (1 −

𝐾𝑞
) × 𝑁𝑞 (𝑡tr −) × Rind.
100
(8)

The overall number of tumor cells at a time “𝑡” is the sum of
sensitive cycling, sensitive quiescent, resistant cycling, resistant quiescent, and dying cells, namely, the following:
𝑁 (𝑡) = 𝑁𝑝 (𝑡) + 𝑁𝑞 (𝑡) + 𝑁𝑟𝑝 (𝑡) + 𝑁𝑟𝑞 (𝑡)
+ 𝑁𝑑1 (𝑡) + 𝑁𝑑2 (𝑡) + 𝑁𝑑3 (𝑡) .

(9)

Both the model M and the standard model can be modified
to include radioresistance, obtaining the “M Res” and “St Res”
models. Parameters for the models are 𝐾 (or 𝐾𝑝, 𝐾𝑞), 𝐷, and
Rini (or Rind).
The framework of our computer program allows building
even more complex models; for example, combining recruitment and resistance models or models with non-constant 𝐾.
These more complex models were not required to fit the data
of the present study.
Using a principle of parsimony we first tested simpler
models, introducing more complex effects only when they
allowed improving the fitting in a statistically significant way
(likelihood ratio test statistics). The program outputs the
complete time course of the tumor volume. In some instances,
alternative models were reported too, not significantly worse
than the best one.
2.2. Fitting Procedure and Sensitivity Analysis. The standard
model has eight independent parameters: 𝑉0 (the tumor
volume at the beginning of treatment), 𝑇𝑑, 𝑇𝑐 (or 𝑇pot ), 𝐺𝐹, 𝛾,
𝐾𝑝, 𝐾𝑞, and 𝐷. The minimal model requires four parameters:
𝑉0, 𝑇𝑑, 𝛾, 𝐾, and 𝐷. An additional parameter is included in
the M Rec and St Rec models (𝛾rec ) and in the M Res or St Res
models (Rini or Rind). Except in the case of pt L1, where we
adopted the value 𝛾 = 0.01 in the model Strec, preliminary
modeling led us to set 𝛾 = 0 because higher values did not
improve the fits.
An estimate of the other growth parameters (𝑇𝑑, 𝑇𝑐, 𝐺𝐹)
was made possible by including into the fit the pretreatment
period between the planning CT scan and the start of
treatment. When the prtreatment volume was not available,
we considered two models with 𝑇𝑑 equal to 25 or 150 days.
For each model, parameters were optimized with a
constrained, nonlinear fitting procedure, maximizing the
likelihood function (𝐿) of the logs of tumor volumes, with
a Gaussian distribution of data errors taking their standard
deviation as a parameter as described before [16]. Likelihoodbased 95% confidence intervals for each parameter were

obtained by raising or lowering its value until 𝐿 was reduced
2
/2 [24].
to the value of log(𝐿) = log(𝐿 best ) − 𝜒0.05,1
2.3. Implementation. All analyses were done with a computer
program using Excel (Microsoft, Redmond, WA) with its
standard features (Visual Basic and Solver). A user-friendly
interface graphically displays the tumor volume simulation.
The program is available for noncommercial purposes.

3. Results
The individual patient, tumor, and treatment characteristics
are detailed in Table 1. The median tumor volume was 3.6 cc
(range 0.4–161.1). The time courses of tumor volume measurements of the 17 patients who received fractionated (group
L, 5 patients) or hypofractionated (group S, 12 patients) RT
were fitted with the M and St models. The simpler M model
was adopted if the fitting was similar between both. Similarly,
the even more complex RES or REC models were adopted
only when they produced a significant improvement over the
fits obtained with the M or St models. Model parameters are
summarized in Table 2. The details of the best fit models for
the tumor volume time course for each patient are reported
in Table 3.
The model fits of group L patients were very close
to experimental data, with a median Δ% (average percent
difference between data and fit) of 5.1% (range 3.5–10.2%) for
the best fitting model. The fits obtained in group S patients
were generally good, with a median Δ% of 7.2% (range 3.7–
23.9%) for the best fitting model and with 9 out of 12 cases
below 10%. Abrupt increases or decreases of volume measures
were sometimes observed in group S but not in group L.
Patients with similar response to treatment were grouped
according to tumor cell killing as “high” (𝐾 or 𝐾𝑝 ≥ 5% in
group L, 𝐾 or 𝐾𝑝 ≥ 35% in group S) or “low” (not “high”),
and the speed of the dying process as “fast” (𝐷 ≥ 0.5) or
“slow” (not “fast”). The responses to treatment were in turn
typed as follows.
(i) Type A: “high” kill and “slow” dying rate.
(ii) Type B: “high” kill and “fast” dying rate.
(iii) Type C: “low” kill and “slow” (or not detectable) dying
rate. Poor responders.
(iv) Type D: “low” kill and “fast” dying rate. Poor responders.
Group L had two Type A responses, two Type B responses,
and one Type C response. Group S had four Type A, three
Type B, two Type C, and three Type D responses. Figures 2 to
4 report the data (circles) and the best fit model (continuous
line) of all measured time courses.
3.1. Type A Response (Figure 2). Type A response is characterized by a relatively high fraction of killed cells per
fraction but a slow dying process, so that shrinkage of the
tumor is delayed in time. Type A response was observed in
patients L4, L5, S1, S7, S10, and S13. The model predicts a slow
continuous shrinkage of the tumor that can continue after
the end of treatment due to delayed loss of killed cells and
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Figure 2: Cell number versus days for patients with a Type A response (high percentage of killed cells and slow dying rate). Gray circles: data
points; white circle: treatment starts; black circles: data assumed equal to the CT detection limit (when they are actually below it); continuous
line: best fit model; dashed lines: subpopulation of resistant cells, either with the initial (Rini) or the induced (Rind) resistance models.
Table 2: Parameter comparison for the four tumor growth and therapy efficacy models.
Model
M: minimal
St: standard
REC: recruitment
RES: resistant

Td
∙
∙
∙
∙

GF
∙
∙
∙

𝑇pot
∙
∙
∙
∙

𝛾

𝛾rec

∙
∙
∙

∙

Parameter
𝐾
𝐾𝑞
∙
∙
∙
I
I

𝐾𝑝
∙
∙
I

𝐷
∙
∙
∙
∙

Rini

Rind

I

I

∙: Essential model parameter.
I: Model parameter options to be selected. RES model uses either parameter 𝐾 or 𝐾𝑝 and 𝐾𝑞 and either Rini or Rind.
Abbreviations:
Td: doubling time; GF: growth fraction; 𝑇pot : tumor potential doubling time; 𝛾: rate at which quiescent cells reenter the cycle (if 𝛾rec is used, this will be the
pretreatment rate); 𝛾rec : recruitment rate 𝛾; 𝐾: fraction of cells killed by a single fraction of RT; 𝐾𝑞: fraction of quiescent cells killed by a single fraction; 𝐾𝑝:
fraction of proliferating cells killed by a single fraction; 𝐷: dying rate; Rini: subpopulation of resistant cells; Rind: fraction of cells that becomes resistant after
each RT exposure.

natural cell loss when treatment has depleted the proliferating
pool. Notice that in three patients (S1, S7, and S13) the last
measurement was below the CT detection limit (indicated
with a black circle). In these cases we conservatively assumed
a measure equal to the CT detection limit, leading to possibly
underestimating an effect that was already estimated as very
high, which did not affect the classification. In the case of
the L patients, the model estimates that each 2.5 Gy fraction
killed 10% (patient L4) to 16% (patient L5) of sensitive tumor
cells. However, the reduction of tumor mass was eventually

exhausted, an effect that was modeled including a subset of
resistant cells. The subpopulation of resistant cells (dashed
lines in Figure 2) became prevalent within six to seven weeks.
The two alternative models of resistance, that is, considering
resistant cells present from the beginning (Rini) or induced
by treatment (Rind), performed similarly in fitting the data so
that the issue of the origin of resistance remained unanswered
with the available data. The “initial resistance” estimates
that about one third of the cells were initially insensitive to
treatment in both cases, while the “induced resistance” model
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25

200
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0.05

0.15
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5.6
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8.4
8.4
5.6
23.6
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9.7
5.8
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5.5

14.3

5.6
13.9
9.3
27.8
5.5
5.6
5.6
22.8

𝑇pot
(days)

0

0
0
0.01

0

0
0

0

0.01

𝛾

0.74§ [0.23–0.79]

0.48§ [0.27– 0.68]

0.26§ [0.05–0.54]

0.02† [0.02–0.02]

0.37‡ [0.19–0.81]

0.10∗ [0.08–0.11]

𝛾rec

22 [20–23]

13 [11–21]

8 [5–11]
25 [5–44]
9 [5–12]

10 [9–12]
16 [14–33]

1.8 [1-2]

15 [14–16]

𝐾
(%)

76 [74–95]
90 [57–99]

99 [98–100]
65 [59–85]
99 [85–100]

90 [38–100]

7 [6-7]
90 [90–100]
90
[86–99.9]
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29 [28–30]

𝐾𝑝
(%)
Rini
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1 [0.85–0.9999]

0.5 [0.46–0.95] 0.20 [0.19–0.21] 3.4 [3.1–3.7]
0.56 [0.47–0.71]
0.2 [0.2–1]
0.6 [0.48–1]
0.3 [0.25–0.4] 0.31 [0.28–0.33] 3.2 [2.7-3.7]
0.35 [0.2–0.7] 0.36 [0.32–0.39] 6.2 [5.8-6.8]
0.36 [0.25–0.42]
0.2 [0.2–0.28]

𝐷

0.999 [0.25–1]
ND
0.2 [0.2–0.4]
2 [0.01–6]
0.2 [0.1–0.62]
1 [0.57–1]
23 [23–25] 0.2 [0.16–0.29]
1 [0–7]
0.9 [0.44–1]
23 [20–25] 0.2 [0.15–0.31]
0.99 [0.95–1]
0.01 [0.01–4] 0.75 [0.1–0.97]
53 [53–99] 0.2 [0.2–0.25]

1 [0–6]

1 [0.5–2]
5 [5–9]

1 [0.5–2]

1 [0.5–2]

𝐾𝑞
(%)

6.6
4.0
3.7
5.1
6.6
9.2
7.2
13.1
23.9
7.2
14.6

6.8

8.0
7.0
3.5
10.2
4.0
5.1
5.4
8.4

Mean
Δ%

Abbreviations:
Pt.: patient; Mean Δ%: average percent difference between data and fit; minimal (M) and standard (St) models are defined in the text, with the respective growth parameters (Td, GF, 𝑇pot , and 𝛾) and killing parameters
(𝐾, 𝐾𝑝, 𝐾𝑞, and 𝐷). For the resistance models, two alternative resistance models (Res) were considered: (i) initial resistance, with parameter Rini (fraction of resistant cells at 𝑡 = 0); (ii) induced resistance, with
parameter Rind (probability of induced resistance per fraction delivered). The recruitment model (Rec) is characterized by the parameter 𝛾rec (fraction of quiescent cells recruited into proliferation per day).
Response types: A: “high” kill and “slow” dying rate; B: “high” kill and “fast” dying rate; C: “low” kill and “slow” dying rate; D: “low” kill and “fast” dying rate.
∗
Recruitment from 4th week after treatment.
†
Recruitment from 3rd week after treatment.
‡
Recruitment on days 1–13 after treatment.
§
Recruitment on days 1–3 after treatment.

12.1

Day 0
volResponse
Model
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type
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B
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13.2
M
C
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161.1 M Res
A
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A
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Table 3: Individual patient, tumor, treatment, and tumor response characteristics. Patient IDs starting with an “L” had a long RT course while those starting with an “S” had a short one. Best
fit values of model parameters with likelihood-based confidence ranges in square brackets.
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Figure 3: Cell number versus days for patients with a Type B response (high percentage of cells killed and fast dying rate). Symbols are as in
Figure 2.

estimates that 3% (patient L4) to 6% (patient L5) of sensitive
cells became resistant after each treatment fraction.
A higher shrinkage was reached in the S patients, without
evidence of resistance. In these cases the standard model
fitted the data significantly better than the minimal model
and suggested that each 10 Gy exposure was able to kill ≥90%
of cycling cells and a variable amount of quiescent cells
ranging from 5% (patient S1) to 53% (patient S13).
3.2. Type B Response (Figure 3). Type B is characterized by
a faster tumor response and high killing rates. Volume time
courses in patients L1, L3, S2, S8, and S12 are representative
of this kind of response. A common landmark of the Type B
response was a recruitment of cells into proliferation, fitted
by St Rec models, although an alternative model including
resistance is also consistent with the data in patient L1.
Recruitment is clearly shown in patient L3 in the first week
of treatment when the tumor size increased at a much higher
rate than it did in the pretreatment period. Only in the second
week the volume started decreasing and produced a rapid
shrinkage of the tumor mass.
In contrast, in the case of patient L1 the tumor started
shrinking shortly after the beginning of treatment. Recruitment occurred late, during the fourth week of therapy. By
analogy with patient L3, if the St Rec model is correct, one
would expect that continuation of RT would have further

reduced the tumor mass in patient L1. Although the recruitment model provides the best fit for patient L1, the resistance
model was not significantly worse and estimated that the lack
of further reduction of the tumor mass around the sixth week
was due to the emergence of a subpopulation of resistant cells.
In this case, prolongation of treatment may have been futile.
As for the other models which include resistance, the data was
insensitive to the kind of resistance applied, either initial, with
about 20% resistant cells at the start of treatment, or induced,
with 3% sensitive cells becoming resistant after each dose.
According to the group L models, each 2.5 Gy dose killed
roughly 16% of tumor cells (patient L1, model M res, 𝐾
parameter) or 30% (patient L1, model St Rec, 𝐾𝑝 parameter)
to 50% (patient L3, model St Rec, 𝐾𝑝 parameter) of cycling
tumor cells, being almost ineffective against quiescent cells.
Recruitment was also detected in group S, although the
short followup of the available data in patients S2 and S8
prevented a robust confirmation of the prediction of tumor
reduction after the end of treatment. Approximately 65% to
90% of cycling cells were killed by each 10 Gy dose, while
quiescent cells were unaffected. The mechanism postulated by
the model is that these tumors had a high fraction (>90%) of
quiescent cells, initially, that were recruited into proliferation
by the first or second 10 Gy dose. Subsequent 10 Gy doses
were extremely effective in killing newly cycling cells and
caused a significant reduction of the tumor mass. At the end
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Figure 4: Cell number versus days for patients with Type C (low percentage of cells killed and slow dying rate) and Type D (low percentage
of cells killed and fast dying rate) responses. Symbols are as in Figure 2.

of the treatment, the pool of cycling cells was so depleted
that surviving quiescent cells were unable to repopulate it in
a short time, and the tumor mass continued to decrease by
natural cell loss, until a new equilibrium was restored at a
much lower tumor mass.
3.3. Types C and D Responses (Figure 4). Types C and D
responses were characterized by low killing, with a slow (Type
C) or high (Type D) dying process resulting in a poor control
of tumor growth.
The time courses for patients L2, S4, and S5 are representative of Type C response, modeled with the minimal
model, with only 2% (group L) and 10% (group S) cells killed
per fraction, respectively. Only a modest variation of tumor
volume was observed over the treatment period denoting a
poor response. However, an alternative explanation exists in
the L2 case: the neoadjuvant chemotherapy likely killed most
of the tumor, and the residual scar tissue masked the actual
tumor volume. In the case of the time courses of patients S4
and S5, the absence of a pretreatment measurement made it
impossible to estimate the doubling time. Fits assumed either
a short (25 days) or a long (150 days) doubling time, but
in both cases the therapy was predicted as poorly effective.
With the shorter 𝑇𝑑, the estimated fraction of killed cells

per fraction was somewhat higher, but the tumor restarted
to grow rapidly after the end of treatment. In the case of S5,
however, the patient received bevacizumab after RT, and this
was not considered in modeling. Thus, long-term predictions
of the real outcome of this patient were impossible due to the
unknown effect of the drug.
Type D is represented only within group S, and the
minimal model provided the best fit. Killing per fraction was
8–13% in S3 and S6, and it was somewhat higher in S11 (22%),
but it was low considering the high dose per fraction (10 Gy).
Due to the fast cell dying process, a reduction of tumor mass
was achieved and seen during treatment. Immediately after
treatment the tumor restarted growing with its unperturbed
rate. In S6 and S11, a short doubling time was estimated by the
model, so that the benefits of the treatment were readily lost
in a few weeks.

4. Discussion
To our knowledge, this is the first study applying mathematical modeling to characterize RT lung tumor volume response
using diagnostic quality CT images prior to each treatment
fraction, and it is the only study characterizing tumor
response in patients receiving 10 Gy × 5 over a 2-week course.
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Other studies have described the magnitude of tumor
regression during RT without modeling. Erridge et al. analyzed electronic portal images in 25 patients treated with 54
to 81 Gy in 2–2.25 Gy per fraction [7]. In 40% of the patients,
the projected area of the tumor regressed by more than 20%
during treatment in at least one projection. Fox et al. studied
22 patients with NSCLC treated with 2 Gy daily fractions to
a median dose of 62 Gy (range 50–74) with 15 (68%) treated
with concurrent chemotherapy. A mean decrease in the
initial GTV of 30% by a nominal dose of 30 Gy and 43% by a
nominal dose of 50 Gy was observed [3]. In another study of 8
patients where the treatment details were not specified, tumor
volume reduction during treatment ranged from 20% to 71%
(end-inspiration) and from 15% to 70% (end-expiration) in
4DCT scans [25]. In all these studies, however, a closer analysis of the time course of the tumor volume was not attempted.
The performance of a locally weighted regression method
to predict tumor volume at a specific time in NSCLC was
successfully explored by Seibert et al. [6]. Patients were
treated at 2 to 2.5 Gy per fraction to 50 to 74 Gy, including
those considered in a previous study by the same group [4].
In 18 lesions, the authors observed a mean decrease in volume
of 2.2% per day (range 0.6 to 5.8 per day), while 2 lesions
showed an increase of up to 2% per day. In this approach the
patterns of the time courses of tumor volume were considered
per se, focusing on a prediction algorithm, with parameters
unrelated to the underlying biological phenomena.
In the present work we adopted a phenomenological
modeling of tumor proliferation and efficacy of treatment.
This modeling approach was previously proven feasible in
rendering the time evolution of breast cancer during preoperative chemotherapy [16]. The proliferation process is simulated in silico depending on parameters which are associated
with the main biological phenomena in play, that is, the interplay between cell cycling, quiescence, and loss for untreated
tumors, to which the effects of treatment are superimposed.
Our modeling enabled us to estimate the percentage of cells
killed by single doses of radiation, which has been rarely
attempted in the clinical environment, and may give important information on an individual patient’s tumor responsiveness. A similar approach was used by Ribba et al. to model
low-grade glioma treated with chemotherapy and radiotherapy [26]. These authors modeled tumor proliferation
including quiescent cells and differential treatment efficacy
within cycling and quiescent cell subpopulations, considering
delayed death. These features are also shared with our model.
To account for quiescent cells, we adopted what we called
the “standard model,” representing a compromise between
the complexity of the phenomenon of tumor proliferation
and the relative simplicity of the time courses of our volume
data. Our modeling approach exploits the theory of an agestructured cell population to render the proliferation process
on the basis of three, potentially measurable, parameters:
doubling time, potential doubling time, and growth fraction,
all taking advantage of the information available on these
parameters in the lung cancer literature. A fourth parameter,
giving the rate of reentering in cycle of quiescent cells, is not
directly measurable, but best fitting of our data required a
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very low value for it, and it was eventually fixed to zero with
a single exception.
For what concerns the treatment model, the information
available in vivo is not sufficient to disclose all the details
observable in vitro, like blocks in specific cell cycle phases or
the balance between repair and apoptosis [27]. At the time
of each dose administration, a fraction of cells destined to
die was selected, only distinguishing the rate of killing in
quiescent from cycling cells, and then we applied a delay
process through which cells committed to die completed the
death process. In order to model the, possibly slow, process
of elimination of killed cells, we assumed that dying cells
stop proliferating and pass through three stages, envisaging
progressive degrees of damage, before they are definitively
lost and cause a decrease in tumor volume [28].
The use of more complex models, in our opinion, was not
justified, leading to overparametrization and the impossibility of estimating the model parameters’ values. On the other
hand, a simpler model would not allow us to properly evaluate
the proliferation process, in keeping with the present-day
biological knowledge of the cell cycle machinery driving it.
In addition, our modeling approach optionally includes
other factors that may influence the tumor response, like
a subpopulation of radioresistant cells or radiation-induced
recruitment of quiescent cells into proliferation, which were
considered only upon the failure of simpler models.
Ultimately, the selected model for each patient fits the
measured time course of tumor volume with good precision,
with differences between the measured volumes and the
model predictions below 10% in most cases. Pretreatment
and long term tumor volume measurements, which were
available in most instances, were crucial for the accuracy of
the model estimates. In particular, long-term measurements
were of greater importance in group S, where the treatment
course was relatively short, and tumor volume reductions
were not always appreciated. In these cases, further weekly
measurements after treatment could have helped characterize
the tumor response more accurately.
The small size of the conventional and hypofractionated
RT groups makes it impossible to compare them in a proper
statistical sense, adjusting for relevant variables. For example,
a higher number of short doubling time estimates were
obtained within group S compared to group L, which could
account for some of the differences between the groups.
However, the estimate of parameters describing radiation
efficacy (i.e., 𝐾 and 𝐷) was robust and poorly sensitive to the
uncertainty of the doubling time (not shown). Instead, 𝑇𝑑 is
obviously an important variable in the resumption of tumor
growth after treatment.
One limitation of this study was that the intra- and
interindividual contouring reliability was not evaluated.
However, since we used the autocontouring planning tool
with a defined window level, variability should have been
minimized. Moreover, predictions of the models rely not
on single points but on the entire time course of measures,
catching the overall trend of the variations of tumor volume
and somewhat buffering the errors of the single measurements. The average discrepancy between the model and the
data suggests that the typical error of a single measurement
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was in the 5–10% range. Despite the above potential limitations, interesting and potentially useful information could be
retrieved by comparison of the best fit models of all patients.
In most cases, single doses were efficient for killing tumor
cells, with typically 90% of cycling cells killed by 10 Gy and
30–50% killed by 2 Gy, with only a few percent quiescent
cells killed (only in three cases more than 5% quiescent cells
were killed by a single fraction). This was sufficient to induce
a sustained tumor regression continuing after the end of
treatment unless a population of radioresistant cells emerged.
Data analysis could have been done in the framework of
mixed-effect models, where individual profiles are generated
from a population model according to a unimodal distribution of parameters’ values, as successfully done by Ribba et
al. [26]. We preferred instead a different perspective aimed
at distinguishing different types of responses that are also
modeled differently (e.g., with or without resistance), starting
from the simplest model and increasing complexity only
when the fitting significantly improves. Based on the types
of responses that have been identified, further studies can be
planned recruiting a number of patients per group suitable for
population-based analyses. Our modeling approach enabled
the recognition of four different types of response and the
interpretation of the kinetics of cell proliferation underlying
each of them. Response types were characterized not only by
different percentages of killed cells per dose (model parameter 𝐾) but also by the velocity of the disappearance of killed
cells (model parameter 𝐷). In the case of response Type A,
characterized by high cell kill with slow dying rate, hypofractionated therapy seemed to be more effective, eventually
producing a higher volume reduction than conventionally
fractionated therapy. In patients receiving conventional RT,
tumor volume was initially reduced, but after 3-4 weeks of
therapy it reached a sort of plateau. This was modeled by
introducing a subpopulation of radioresistant tumor cells,
whose presence would not have been detectable until it
prevailed over the subpopulation of sensitive cells, depleted
by treatment. Several studies of mathematical modeling of
resistance have been published, mainly focusing on the
emergence of the phenomenon [29–31], with one based on
time-course datasets from patients during/after the treatment
of hematological cancers [32].
We compared two models of resistance: one model
assuming that a subset of resistant cells was already present
at the beginning of treatment and the other assuming that
resistance was induced by treatment. Unfortunately the data
were fitted well by both models, the former estimating that
20–40% of the cells were initially resistant and the other estimating that 3–6% of cells became resistant after each fraction.
Thus data were consistent with the presence of resistance but
were insensitive to the underlying mechanism. There are very
few studies of induced radiation resistance in the literature,
but at least one experiment suggested that this could exist in
the context of crossing over from doxorubicin and radiation,
and vice versa [33]. This may be an area worth investigating,
and develop strategies to overcome resistance with targeted
therapeutic agents.
In the cases we modeled including resistance, further
long-term response in the posttreatment period cannot be
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excluded a priori, but the available data, up to the second
month from treatment start, do not justify this hypothesis.
Other studies suggesting that a very late response is possible
mostly refer to combined radiochemotherapy and were not
designed to recognize an intermediate plateau [1, 5].
No plateau was instead observed in Type A patients
receiving hypofractionated RT, where the model predicts a
continuous shrinkage of the tumor long after the end of the
treatment. This effect was due not only to the delayed loss of
cells killed during the treatment but also to the natural cell
loss occurring in surviving quiescent cells, in a scenario when
the very few surviving cycling cells were unable to sustain an
increase of the overall tumor cell population.
A different model was required to fit response Type
B, characterized by high cell kill with fast dying rate and
by a period of time when quiescent cells were recruited
into proliferation. Cell recruitment from quiescence into
proliferation can be due to increased availability of nutrients
or reoxygenation of hypoxic regions [34–36], in the first
days of therapy. In a single case (patient L1) recruitment
was observed later, in keeping with the traditional view that
accelerated repopulation occurs weeks after the initiation
of radiotherapy [37]. However for patient L1 an alternative
model with a subpopulation of resistant cells, similar to
response Type A, cannot be ruled out, despite that the fit with
the recruitment model was somewhat better.
Response Types C and D, characterized by a low percentage of cells killed per fraction, were found in the remaining six
cases of our series. In these cases the treatment was apparently
less effective, but the correspondence of the measured volume
with the tumor volume may be questioned in some of these
cases. In patient L2, the presence of fibrotic tissue after
neoadjuvant chemotherapy would explain why there was no
further decrease in volume during RT. A similar pitfall was
underlined by Bosmans et al. who explained an unexpected
absence of decrease in the volume during the first 2 weeks of
radiotherapy in chemotherapy-pretreated patients, despite an
accelerated course [2] and contrary to two other studies [4, 7],
by hypothesizing that cell death was offset by treatmentinduced inflammation which increased the volume. These
examples suggest that delivery of neoadjuvant chemotherapy
and the resulting tumor appearance on CT may not correlate
well with the actual tumor volume. Some explanations for
this could be treatment-related fibrosis, atelectasis, or other
treatment-related effects [38]. Incorporating other imaging
modalities such as PET/CT may also be useful for improving
the models.
For what concerns the other Types C and D responses,
misinterpretation of the volume measurements is possible at
least for patients S3 and S5. In the case of S3, fibrosis is suspect
for the long-term datum, which is crucial for modeling of this
case. Patient S5 had a biopsy proven recurrence after receiving
5000 cGy in 250 cGy fractions. The patient also received
neoadjuvant, concurrent, and adjuvant erlotinib (150 mg) and
bevacizumab (15 mg/kg) for this course of RT. The effect
of chemotherapy was not included in modeling. Moreover,
it is possible that fibrotic tissue from the prior course of
RT and/or neoadjuvant chemotherapy could account for the
lack of volume reduction during the present course of RT.
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Nevertheless, approximately one month later the volume had
decreased by 22%.
The fact that for group S there is a visible tumor during
the two-week course of treatment is both reassuring and
perplexing. It is reassuring because group S having a visible
lesion will benefit from more accurate targeting with image
guided radiation therapy (IGRT) and gating techniques. It
is perplexing because despite a biologically equivalent dose
in 2 Gy fractions (EQD2 ) of 66.7 Gy210 delivered (10 Gy × 4
at the time of the last CT) in a short two-week period, 5 of
12 patients in this group were classified as poor responders
(response Types “C” and “D”).
Takeda et al. analyzed 63 patients treated with 10 Gy × 5
fractions and the 3-year local control in patients with Stages
1A and 1B being 93% and 96% [39]. Therefore, the lack of
an early response in some of our group S patients may not
translate to a subsequent poor local control. The apparent lack
of response could be attributed to treatment-related fibrosis,
which is a common clinical explanation for these CT findings.
However, without a biopsy it is difficult to determine if there
was residual disease.
The observation that quiescent cells responded poorly to
radiotherapy suggests that a single fraction treatment may be
suboptimal compared to a short hypofractionated course. The
former would treat a larger proportion of “resistant” quiescent cells, while the latter would have induced cells into the
very radiosensitive proliferation phase by the second fraction.
In addition, higher doses than expected may be required in
the single dose setting to compensate for the radioresistant
quiescent cells.
This type of modeling and treatment response characterization may provide useful insights when trying to understand what is happening at the cellular level or comparing
treatments. Type B, high kill and fast dying rate, tumor
response would be ideal from a palliative perspective in most
situations. This analysis underlines the difficulty of predicting the tumor’s long-term behavior based on the first days of
volume measurements because some effects (e.g., resistance)
may actually emerge after a long time, being totally undetectable in the first days. Statistically, it would be possible to
estimate a probability of outcomes within each response type,
but this would require a higher number of patients than those
included in this study.

5. Conclusion
The models used in this study performed well in fitting
the available dataset. According to the values of parameters
corresponding to cells killed and cells dying, patients were
grouped in four response types. The models provided useful
insights into the possible underlying mechanisms responsible
for the radiotherapy tumor volume response. Further studies
are necessary to better understand the clinical implications of
the four response types.
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